SREBF1 and steatosis: Benefits of dual therapy were most evident for steatosis and congestion, whereas biochemical endpoints showed no consistent advantage over DAPA alone—consistent with reports that DAPA limits hepatic lipid accumulation/inflammation via FoxO1 and SREBP-1c [19], and that TMZ reduces ischemia–reperfusion injury by supporting ATP production [25].